> top > docs > PMC:2065877 > spans > 29068-29306 > annotations

PMC:2065877 / 29068-29306 JSONTXT

Annnotations TAB JSON ListView MergeView

pmc-enju-pas

Id Subject Object Predicate Lexical cue
T11983 0-7 RB denotes However
T11984 7-8 -COMMA- denotes ,
T11985 9-12 DT denotes the
T11986 13-21 VB denotes enhanced
T11987 22-31 NN denotes viability
T11988 32-34 IN denotes of
T11989 35-39 NN denotes LMP1
T11990 40-50 JJ denotes transgenic
T11991 51-62 NN denotes lymphocytes
T11992 63-66 VB denotes was
T11993 67-78 RB denotes effectively
T11994 79-86 VB denotes blocked
T11995 87-89 IN denotes by
T11996 90-99 NN denotes treatment
T11997 100-104 IN denotes with
T11998 105-116 NN denotes triciribine
T11999 116-117 -COMMA- denotes ,
T12000 118-128 NN denotes BAY11–7085
T12001 128-129 -COMMA- denotes ,
T12002 130-142 NN denotes cucurbitacin
T12003 143-144 NN denotes I
T12004 144-145 -COMMA- denotes ,
T12005 146-149 CC denotes and
T12006 150-158 RB denotes slightly
T12007 159-163 IN denotes with
T12008 164-172 NN denotes SB203580
T12009 172-173 -COMMA- denotes ,
T12010 174-177 CC denotes but
T12011 178-181 RB denotes not
T12012 182-184 IN denotes by
T12013 185-194 NN denotes treatment
T12014 195-199 IN denotes with
T12015 200-209 NN denotes rapamycin
T12016 209-210 -COMMA- denotes ,
T12017 211-216 NN denotes U0126
T12018 216-217 -COMMA- denotes ,
T12019 218-220 CC denotes or
T12020 221-226 NN denotes AG490
T12021 227-228 -LRB- denotes (
T12022 228-234 NN denotes Figure
T12023 235-236 CD denotes 7
T12024 236-237 -RRB- denotes )
R8973 T11987 T11985 arg1Of viability,the
R8974 T11987 T11986 arg2Of viability,enhanced
R8975 T11987 T11988 arg1Of viability,of
R8976 T11987 T11992 arg1Of viability,was
R8977 T11987 T11994 arg2Of viability,blocked
R8978 T11991 T11988 arg2Of lymphocytes,of
R8979 T11991 T11989 arg1Of lymphocytes,LMP1
R8980 T11991 T11990 arg1Of lymphocytes,transgenic
R8981 T11994 T11983 arg1Of blocked,However
R8982 T11994 T11984 arg1Of blocked,","
R8983 T11994 T11992 arg2Of blocked,was
R8984 T11994 T11993 arg1Of blocked,effectively
R8985 T11994 T11997 arg1Of blocked,with
R8986 T11994 T12007 arg1Of blocked,with
R8987 T11994 T12012 arg1Of blocked,by
R8988 T11996 T11994 arg1Of treatment,blocked
R8989 T11996 T11995 arg2Of treatment,by
R8990 T11997 T12005 arg1Of with,and
R8991 T11998 T11999 arg1Of triciribine,","
R8992 T11999 T12001 arg1Of ",",","
R8993 T12000 T11999 arg2Of BAY11–7085,","
R8994 T12001 T11997 arg2Of ",",with
R8995 T12003 T12001 arg2Of I,","
R8996 T12003 T12002 arg1Of I,cucurbitacin
R8997 T12005 T12004 arg1Of and,","
R8998 T12005 T12010 arg1Of and,but
R8999 T12007 T12005 arg2Of with,and
R9000 T12007 T12006 arg1Of with,slightly
R9001 T12008 T12007 arg2Of SB203580,with
R9002 T12010 T12009 arg1Of but,","
R9003 T12012 T12010 arg2Of by,but
R9004 T12012 T12011 arg1Of by,not
R9005 T12013 T12012 arg2Of treatment,by
R9006 T12013 T12014 arg1Of treatment,with
R9007 T12015 T12016 arg1Of rapamycin,","
R9008 T12016 T12019 arg1Of ",",or
R9009 T12017 T12016 arg2Of U0126,","
R9010 T12019 T12014 arg2Of or,with
R9011 T12019 T12018 arg1Of or,","
R9012 T12020 T12019 arg2Of AG490,or
R9013 T12020 T12021 arg1Of AG490,(
R9014 T12022 T12021 arg2Of Figure,(
R9015 T12022 T12023 arg1Of Figure,7
R9016 T12024 T12021 arg3Of ),(

bionlp-st-ge-2016-spacy-parsed

Id Subject Object Predicate Lexical cue
T12851 0-7 RB denotes However
T12852 7-8 , denotes ,
T12853 9-12 DT denotes the
T12854 13-21 JJ denotes enhanced
T12855 22-31 NN denotes viability
T12856 32-34 IN denotes of
T12857 35-39 CD denotes LMP1
T12858 40-50 JJ denotes transgenic
T12859 51-62 NNS denotes lymphocytes
T12860 63-66 VBD denotes was
T12861 67-78 RB denotes effectively
T12862 79-86 VBN denotes blocked
T12863 87-89 IN denotes by
T12864 90-99 NN denotes treatment
T12865 100-104 IN denotes with
T12866 105-116 NN denotes triciribine
T12867 116-117 , denotes ,
T12868 118-123 NNP denotes BAY11
T12869 124-128 CD denotes 7085
T12870 128-129 , denotes ,
T12871 130-142 NN denotes cucurbitacin
T12872 143-144 PRP denotes I
T12873 144-145 , denotes ,
T12874 146-149 CC denotes and
T12875 150-158 RB denotes slightly
T12876 159-163 IN denotes with
T12877 164-172 CD denotes SB203580
T12878 172-173 , denotes ,
T12879 174-177 CC denotes but
T12880 178-181 RB denotes not
T12881 182-184 IN denotes by
T12882 185-194 NN denotes treatment
T12883 195-199 IN denotes with
T12884 200-209 NN denotes rapamycin
T12885 209-210 , denotes ,
T12886 211-216 NNP denotes U0126
T12887 216-217 , denotes ,
T12888 218-220 CC denotes or
T12889 221-226 NNP denotes AG490
T12890 227-228 -LRB- denotes (
T12891 228-234 NNP denotes Figure
T12892 235-236 CD denotes 7
T12893 236-237 -RRB- denotes )
T12894 237-238 . denotes .
R9759 T12851 T12862 advmod However,blocked
R9760 T12852 T12862 punct ",",blocked
R9761 T12853 T12855 det the,viability
R9762 T12854 T12855 amod enhanced,viability
R9763 T12855 T12862 nsubjpass viability,blocked
R9764 T12856 T12855 prep of,viability
R9765 T12857 T12859 nummod LMP1,lymphocytes
R9766 T12858 T12859 amod transgenic,lymphocytes
R9767 T12859 T12856 pobj lymphocytes,of
R9768 T12860 T12862 auxpass was,blocked
R9769 T12861 T12862 advmod effectively,blocked
R9770 T12862 T12862 ROOT blocked,blocked
R9771 T12863 T12862 agent by,blocked
R9772 T12864 T12863 pobj treatment,by
R9773 T12865 T12862 prep with,blocked
R9774 T12866 T12865 pobj triciribine,with
R9775 T12867 T12866 punct ",",triciribine
R9776 T12868 T12866 appos BAY11,triciribine
R9777 T12869 T12866 appos 7085,triciribine
R9778 T12870 T12866 punct ",",triciribine
R9779 T12871 T12866 conj cucurbitacin,triciribine
R9780 T12872 T12871 conj I,cucurbitacin
R9781 T12873 T12872 punct ",",I
R9782 T12874 T12872 cc and,I
R9783 T12875 T12876 advmod slightly,with
R9784 T12876 T12862 prep with,blocked
R9785 T12877 T12876 pobj SB203580,with
R9786 T12878 T12862 punct ",",blocked
R9787 T12879 T12862 cc but,blocked
R9788 T12880 T12881 neg not,by
R9789 T12881 T12862 conj by,blocked
R9790 T12882 T12881 pobj treatment,by
R9791 T12883 T12881 conj with,by
R9792 T12884 T12883 pobj rapamycin,with
R9793 T12885 T12884 punct ",",rapamycin
R9794 T12886 T12884 conj U0126,rapamycin
R9795 T12887 T12886 punct ",",U0126
R9796 T12888 T12886 cc or,U0126
R9797 T12889 T12886 conj AG490,U0126
R9798 T12890 T12891 punct (,Figure
R9799 T12891 T12889 appos Figure,AG490
R9800 T12892 T12891 nummod 7,Figure
R9801 T12893 T12889 punct ),AG490
R9802 T12894 T12862 punct .,blocked

sentences

Id Subject Object Predicate Lexical cue
T11846 0-238 Sentence denotes However, the enhanced viability of LMP1 transgenic lymphocytes was effectively blocked by treatment with triciribine, BAY11–7085, cucurbitacin I, and slightly with SB203580, but not by treatment with rapamycin, U0126, or AG490 (Figure 7).
T202 0-238 Sentence denotes However, the enhanced viability of LMP1 transgenic lymphocytes was effectively blocked by treatment with triciribine, BAY11–7085, cucurbitacin I, and slightly with SB203580, but not by treatment with rapamycin, U0126, or AG490 (Figure 7).

events-check-again

Id Subject Object Predicate Lexical cue
T13940 35-39 Protein denotes LMP1

bionlp-st-ge-2016-reference-tees

Id Subject Object Predicate Lexical cue
T13821 35-39 Protein denotes LMP1
T13822 118-144 Protein denotes BAY11–7085, cucurbitacin I

bionlp-st-ge-2016-reference

Id Subject Object Predicate Lexical cue
T11751 35-39 Protein denotes LMP1

bionlp-st-ge-2016-uniprot

Id Subject Object Predicate Lexical cue
T12675 35-39 P03230 denotes LMP1

test2

Id Subject Object Predicate Lexical cue Negation
T11663 35-39 Protein denotes LMP1
T11664 79-86 Negative_regulation denotes blocked true